On January 3, 2020 Accelerate Diagnostics, Inc. (NASDAQ: AXDX) reported that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2020, at 11:30 a.m. Pacific Time (Press release, ACCELERATED MEDICAL DIAGNOSTICS, JAN 3, 2020, View Source [SID1234552690]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the company’s investor relations website at ir.axdx.com. A replay of the webcast will be available for at least 30 days following the conference.

On January 3, 2020 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 6:00 p.m. ET, followed by a question and answer session at 6:30 p.m. ET (Press release, BD Pharmaceutical Systems, JAN 3, 2020, View Source [SID1234552689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live webcasts of BD’s presentations can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Tuesday, January 21, 2020.

On January 3, 2020 McKesson Corporation (NYSE:MCK) reported that its third quarter fiscal 2020 financial results will be released before market open on Tuesday, February 4, 2020 (Press release, McKesson, JAN 3, 2020, View Source [SID1234552688]). The company will host a conference call at 8:00 AM Eastern Time to discuss the financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the conference call will be available on McKesson’s Investor Relations website at View Source, along with the company’s earnings press release, financial tables and slide presentation. The conference call can also be accessed by dialing 786-815-8297. The password is ‘McKesson’.

On January 3, 2020 NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, reported that it will present a company overview at the Biotech Showcase 2020 conference, taking place at the Hilton Union Square in San Francisco, CA (Press release, NeoImmuneTech, JAN 3, 2020, View Source [SID1234552686]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NeoImmuneTech’s Chief Business Officer, Samuel Zhang, Ph.D., MBA, will review NeoImmuneTech’s recent progress and future directions, including an update on the company’s lead drug candidate, Hyleukin-7. NeoImmuneTech is currently conducting several clinical trials of Hyleukin-7 in different types of cancer and multiple pre-IND and non-clinical studies in both solid tumors and hematologic malignancies.

Presentation details:
Date: Tuesday, January 14
Time: 3:00pm PT
Track: Franciscan B (Ballroom Level)
Location: Hilton Hotel, Downtown San Francisco, CA

About Hyleukin-7

Hyleukin-7, the only clinical-stage long-acting human IL-7, is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for T-cell development and for sustaining immune response to chronic antigens (as in cancer). Hyleukin-7’s favorable PK/PD and safety profiles make it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. Hyleukin-7 is being studied in multiple clinical trials in solid tumors, and is being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

On January 3, 2020 Tracon Pharmaceuticals presented the corporate presentation (Presentation, Tracon Pharmaceuticals, JAN 3, 2020, View Source [SID1234552685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!